Specifications

Specificity: Th1 response

Working concentration: 10 - 100 μg/mouse

Endotoxin level: <1 EU/mg

Solubility: 5 mg/ml in physiological water (NaCl 0.9%) heated for 10 minutes at 65 - 70°C

Documents

• TDS Poly(I:C) (HMW) VacciGrade : 10 mg (vac-pic)
• MSDS Poly(I:C) (HMW) VacciGrade : 10 mg (vac-pic)

Contents

• 10 mg of lyophilized Poly(I:C) HMW VacciGrade™
• 10 ml sterile endotoxin-free physiological water (NaCl 0.9%)
Note: This product is dispensed by weight of dry material. This weight includes polymer, residual salt and residual water. Content of polymer may vary from lot to lot.

Poly(I:C) HMW VacciGrade™ is shipped at room temperature and should be stored at 4°C. Lyophilized product is stable 1 year at 4°C when properly stored. Upon resuspension, prepare aliquots of Poly(I:C) VacciGrade™ and store at -20°C for long term storage. Store at 4°C for short term storage. Resuspended product is stable 1 month at 4°C and 1 year at -20°C. Avoid repeated freeze-thaw cycles

Description

Polyinosinic-polycytidylic acid (poly(I:C)) is a synthetic analog of double stranded RNA (dsRNA), a molecular pattern associated with viral infection. Poly(I:C) can activate the immune response through two distinct pathogen recognition receptors (PRRs)  [1]. Endosomal poly(I:C) activates TLR3 while cytosolic poly(I:C) activates RIG-I/MDA-5. Triggering the TLR3 pathway induces IL-12 and type I IFNs production, and improves MHC class II expression and cross-presentation of antigen  [1]. Stimulation of MDA-5 enhances the production of type I IFNs that play a critical role in enhancing T and B cell immunity  [1]. Poly(I:C) promotes Th1 (cellular) biased immunity through its induction of IL-12 and type I IFNs [1].

Poly(I:C) has been tested as an adjuvant in numerous animal models  [2-9]. Promising results have been obtained using poly(I:C) as an adjuvant in flu vaccine delivered intranasally to mice [2]. Poly(I:C) has also been shown to enhance the efficacy of peptide-based cancer vaccines by promoting tumor specific T cell responses in mice  [3-6]. Immunization of mice with poly(I:C) resulted in a strong Th1 response  [7] and high levels of serum type I IFN [8]. 

1. Coffman RL. et al., 2010. Vaccine adjuvants: Putting innate immunity to work. Immunity 33(4):492-503.
2. Ichinohe T. et al., 2005. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol. 79(5):2910–2919.
3. Pulko V. et al., 2009. TLR3-stimulated dendritic cells upregulate B7-H1expression and influence the magnitude of CD8 T cell responses to tumor
vaccination. J Immunol 183(6):3634–3641.
4. Currie AJ. et al., 2008. Targeting the effector site with IFN-alpha beta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J Immunol 180(3):1535–1544.
5. Salem ML. et al., 2005. .Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling:evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother 28(3):220–228.
6. Celis E. 2007. Toll like receptor ligands energize peptide vaccines through multiple paths. Cancer Res. 67(17):7945–7947.
7. Fransen F. et al., 2007. Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria
meningitidis serogroup B. Infect Immun 75: 5939-46.
8. Longhi MP. et al., 2009. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 206: 1589-602.
9. stahl-Hennig C. et al., 2009. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog 5:e1000373.